While reaction to today's announcement may seem muted, there was always going to be a pull back in the shareprice.
Nothing to be concerned about at all, Azer-cel is wonderful technology and a game changer in anyone's language, but I still see Oncarlytics as the family jewel here.
Every other Car-T manufacturer is going to need this or another CD19 targeted technology to get into the solid tumours market, if they aren't, then their profits are going to be hugely under threat.
Whatever the next six months brings, Imugene shareholders are in for one hell of a ride.
DYOR opinion only
Ann: Azer-cel Hits Major Milestone in Phase 1b CAR T Trial, page-155
-
- There are more pages in this discussion • 88 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.8¢ |
Change
-0.002(4.00%) |
Mkt cap ! $356.9M | |||
| Open | High | Low | Value | Volume |
| 5.0¢ | 5.0¢ | 4.7¢ | $2.298M | 47.86M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 1925982 | 4.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.9¢ | 3452098 | 12 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| IMU (ASX) Chart |